# CALGB 90601 (NCT00942331)

> Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

No report yet. It can be ordered.

- Drugs tested: bevacizumab
- Indication: advanced urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00942331
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Advanced Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Prostate Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Stage IV Bladder Urothelial Carcinoma AJCC v7; Stage IV Prostate Cancer AJCC v7; Stage IV Renal Pelvis Cancer AJCC v7; Stage IV Ureter Cancer AJCC v7; Stage IV Urethral Cancer AJCC v7; Unresectable Urothelial Carcinoma
- Interventions: Bevacizumab; Cisplatin; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis; Placebo Administration
- Enrollment: 506
- Primary outcome: Overall Survival (OS)

## Indexed commentary on CALGB 90601 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 18 posts on X
- 1 YouTube video

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=calgb-90601-nct00942331

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00942331", "email": "<work email>"}; the inbox owner confirms by the emailed link.